Edition:
United States

Profile: Otonomy Inc (OTIC.O)

OTIC.O on Nasdaq

2.33USD
20 Aug 2019
Change (% chg)

$-0.01 (-0.43%)
Prev Close
$2.34
Open
$2.33
Day's High
$2.35
Day's Low
$2.28
Volume
39,390
Avg. Vol
39,841
52-wk High
$3.20
52-wk Low
$1.50

Otonomy, Inc., incorporated on May 6, 2008, is a biopharmaceutical company. The Company focuses on the development and commercialization of therapeutics for diseases and disorders of the ear. The Company's product candidates include OTIPRIO, OTO-104 and OTO-311. It also has various other product candidates, which target sensorinerual hearing loss, including age-related hearing loss, also known as presbycusis. It is evaluating various approaches to treat this condition, including repair of damaged ribbon synapses and regeneration of cochlear hair cells. The Company's product candidates utilize its formulation technology that combines a thermosensitive gel with drug microparticles to enable a single dose treatment by a physician.

OTIPRIO (ciprofloxacin otic suspension)

The Company's product candidate, OTIPRIO, is a single-dose, physician-administered antibacterial, which is used for the treatment of pediatric patients with bilateral otitis media with effusion undergoing tympanostomy tube placement (TTP) surgery and is available for commercial purchase. The Company is also evaluating OTIPRIO for label expansion in acute otitis externa, also known as swimmer's ear, and acute otitis media with tympanostomy tube (AOMT).

OTO-104: Sustained-Exposure Steroid for Inner Ear Disorders

The Company's product candidate, OTO-104, is a sustained-exposure formulation of the steroid dexamethasone in development for the treatment of Meniere's disease and other inner ear conditions. OTO-104 for Meniere's disease has been granted Fast Track designation by the United States Food and Drug Administration (FDA).

OTO-311: Sustained-Exposure Treatment for Tinnitus

The Company's product candidate, OTO-311, is a sustained-exposure formulation of the N-Methyl-D-Aspartate (NMDA) receptor antagonist gacyclidine in development for the treatment of tinnitus. It has completed a Phase I clinical safety trial for OTO-311.

The Company competes with Arbor Pharmaceuticals, LLC, Auris Medical Holding AG, Autifony Therapeutics Ltd., Fennec Pharmaceuticals Inc., Kyorin Pharmaceutical Co. Ltd., Laboratorios SALVAT S.A., Novartis AG, Otic Pharma Ltd., Otologic Pharmaceutics Inc., Sensorion SA, Sound Pharmaceuticals Inc., Strekin AG and Synphora AB.

Company Address

Otonomy Inc

4796 Executive Dr
SAN DIEGO   CA   92121-3090
P: +1619.3232200
F: +1302.6365454

Company Web Links